SALT LAKE CITY, Jan. 25 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. announced today that it has filed a shelf registration statement with the Securities and Exchange Commission (SEC) to permit the company, from time to time, to offer and sell securities under revised SEC regulations that took effect in December 2005. Under the revised SEC regulations, the shelf registration statement became effective immediately upon filing. In connection with today’s filing, NPS retired its previous shelf registration statement that was declared effective by the SEC in 2005.
NPS chairman and CEO Hunter Jackson, Ph.D., stated, “We have decided to take advantage of new SEC regulations which offer NPS greater flexibility in raising capital as a ‘well-known seasoned issuer.’ We have no plans at this time to raise additional capital under the new registration statement but want to have the ability to be opportunistic and flexible in funding our operations under the new SEC rules.”
NPS discovers, develops and commercializes small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has one FDA approved product, one product candidate undergoing regulatory review for approval to market in the U.S. and Europe, as well as other drug candidates in various stages of clinical development backed by a strong discovery research effort. Additional information is available on the company’s website, www.npsp.com.
NPS Pharmaceuticals, Inc.
CONTACT: Brandi L. Simpson, Sr. Director, Investor Relations of NPSPharmaceuticals, Inc., +1-801-583-4939
Web site: http://www.npsp.com/
Company News On-Call: http://www.prnewswire.com/comp/613587.html /
